title: Clinical effect of naftopidil on the quality of life of patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a prospective study.
abstract: OBJECTIVE
  To investigate the benefit of alpha1-adrenoceptor antagonist naftopidil on the quality of life (QOL) of patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (BPH/LUTS).
  
  
  METHODS
  A total of 99 men with BPH/LUTS were prospectively recruited. The Short Form-8 (SF-8) was used for generic QOL assessment and each parameter was compared with the norm in these patients. Longitudinal changes were evaluated using the SF-8 and the International Prostatic Symptoms Score (I-PSS) at baseline, 4 and 8 weeks after naftopidil administration. The relationship between SF-8 and I-PSS was analyzed.
  
  
  RESULTS
  Five of eight components in the SF-8 were significantly lower than the Japanese national norm at baseline. SF-8 score was improved by naftopidil at 4 and 8 weeks in general health (GH) and physical component summary (PCS) in the patients in their 70s. Mental health (MH) and mental component summary (MCS) were improved at 8 weeks in patients in their 60s. When analyzing the whole cohort, SF-8 GH, role emotional (RE) and MH had improved at 8 weeks, which was similar to the norm, and bodily pain (BP) results were better. Compared with the baseline, total I-PSS, storage/voiding symptoms and QOL index scores improved significantly under naftopidil. Each component of I-PSS (except for hesitancy) correlated with SF-8 sub-scales (except for BP) to some extent.
  
  
  CONCLUSIONS
  BPH/LUTS impairs generic QOL, which is improved by naftopidil treatment. SF-8 can be a useful instrument to assess the efficacy of BPH/LUTS treatment because its simplicity to complete and analyze, and its meaningful relationship to I-PSS.
authors.affiliation: Department of Urology, Chiba University Graduate School of Medicine, Chiba, Japan. komiya@med.utoyama.ac.jp
authors.forename: Akira
authors.initials: A
authors.lastname: Komiya
authors.forename: Hiroyoshi
authors.initials: H
authors.lastname: Suzuki
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Awa
authors.forename: Ken-ichi
authors.initials: K
authors.lastname: Egoshi
authors.forename: Tetsuro
authors.initials: T
authors.lastname: Onishi
authors.forename: Hiroomi
authors.initials: H
authors.lastname: Nakatsu
authors.forename: Takemasa
authors.initials: T
authors.lastname: Ohki
authors.forename: Kazuo
authors.initials: K
authors.lastname: Mikami
authors.forename: Naohide
authors.initials: N
authors.lastname: Sato
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Araki
authors.forename: Sho
authors.initials: S
authors.lastname: Ota
authors.forename: Yukio
authors.initials: Y
authors.lastname: Naya
authors.forename: Tomohiko
authors.initials: T
authors.lastname: Ichikawa
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D000368:Aged; D006801:Humans; D008297:Male; D009281:Naphthalenes / Q000627:therapeutic use*; D010879:Piperazines / Q000627:therapeutic use*; D011446:Prospective Studies; D011470:Prostatic Hyperplasia / Q000150:complications*; D053448:Prostatism / Q000188:drug therapy* / Q000209:etiology*; D011788:Quality of Life; D011795:Surveys and Questionnaires
chemical_list: D000317:Adrenergic alpha-Antagonists; D009281:Naphthalenes; D010879:Piperazines; C064357:naftopidil